Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

[Study of thromboxane A2 antagonist reduction in the treatment of patients with perennial allergic rhinitis].

Authors: Narita, Shinichiro  Shirasaki, Hideaki  Itoh, Junichi  Kobayashi, Kazutoyo  Himi, Tetsuo 
Citation: Narita S, etal., Arerugi. 2004 Jun;53(6):601-4.
Pubmed: (View Article at PubMed) PMID:15247523

We investigated whether or not we could reduce the medication for patients with perennial allergic rhinitis after improvement of the nasal symptoms. We administered the thromboxane A2 receptor antagonist Ramatroban, which also improves non-specific hypersensitivity, for 4 weeks and then reduced the dose to half for 4 weeks and investigated the severity of general symptoms and each nasal symptom (sneeze, rhinorrhea, and congestion). There was a significant improvement in the severity of general symptoms and each nasal symptom for the first 4 weeks (p<0.01), which was maintained for 4 weeks after reduction of the dose (n=14). There was no difference in the severity of symptoms between the reduced dosage (n=14) and the maintained dosage (n=15) groups. We also investigated the level of eosinophilia in nasal smears before and after the treatment (n=14) and showed that the level was significantly (p<0.01) reduced after the start of treatment. In conclusion, it was noted that we could reduce the dose of Ramatroban after the improvement of nasal symptoms on patients with perennial allergic rhinitis.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 11059532
Created: 2016-04-15
Species: All species
Last Modified: 2016-12-30
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.